+

CL2008001580A1 - Anticuerpo que se une al glibulomero beta amiloide abeta(20-42); acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; metodo para tratar una enfermedad relacionada con glomerulo abeta (20-42) y diagnosticar una enfermedad asociada a este globulomero abeta(20-42). - Google Patents

Anticuerpo que se une al glibulomero beta amiloide abeta(20-42); acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; metodo para tratar una enfermedad relacionada con glomerulo abeta (20-42) y diagnosticar una enfermedad asociada a este globulomero abeta(20-42).

Info

Publication number
CL2008001580A1
CL2008001580A1 CL2008001580A CL2008001580A CL2008001580A1 CL 2008001580 A1 CL2008001580 A1 CL 2008001580A1 CL 2008001580 A CL2008001580 A CL 2008001580A CL 2008001580 A CL2008001580 A CL 2008001580A CL 2008001580 A1 CL2008001580 A1 CL 2008001580A1
Authority
CL
Chile
Prior art keywords
abeta
globulomer
binds
antibody
treat
Prior art date
Application number
CL2008001580A
Other languages
English (en)
Inventor
Barghorn Stefan
Hillen Heinz
Keller Patrick
R Striebinger Andreas
Labkovsky Boris
R Hinton Paul
M Juan Veronica
Original Assignee
Abbott Lab
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001580(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Abbott Gmbh & Co Kg filed Critical Abbott Lab
Publication of CL2008001580A1 publication Critical patent/CL2008001580A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Proteína de unión que comprende un dominio de unión a antígeno que se une al globulómero beta amiloide (20-42); ácido nucleico que lo codifica; método de producción; composición farmacéutica que la comprende; anticuerpo que la comprende; y método para tratar una enfermedad relacionada con globulómero beta amiloide (20-42).
CL2008001580A 2007-05-30 2008-05-30 Anticuerpo que se une al glibulomero beta amiloide abeta(20-42); acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; metodo para tratar una enfermedad relacionada con glomerulo abeta (20-42) y diagnosticar una enfermedad asociada a este globulomero abeta(20-42). CL2008001580A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94093207P 2007-05-30 2007-05-30
US99035907P 2007-11-27 2007-11-27

Publications (1)

Publication Number Publication Date
CL2008001580A1 true CL2008001580A1 (es) 2008-12-05

Family

ID=39791050

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001580A CL2008001580A1 (es) 2007-05-30 2008-05-30 Anticuerpo que se une al glibulomero beta amiloide abeta(20-42); acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; metodo para tratar una enfermedad relacionada con glomerulo abeta (20-42) y diagnosticar una enfermedad asociada a este globulomero abeta(20-42).

Country Status (22)

Country Link
US (1) US20090175847A1 (es)
EP (1) EP2150563A1 (es)
JP (1) JP2010530740A (es)
KR (1) KR20100032398A (es)
CN (1) CN101827862A (es)
AR (1) AR066794A1 (es)
AU (1) AU2008260062A1 (es)
BR (1) BRPI0812005A2 (es)
CA (1) CA2687414A1 (es)
CL (1) CL2008001580A1 (es)
CO (1) CO6251291A2 (es)
CR (1) CR11179A (es)
DO (1) DOP2009000269A (es)
EC (1) ECSP099833A (es)
IL (1) IL202243A0 (es)
MX (1) MX2009012950A (es)
PA (1) PA8782201A1 (es)
PE (1) PE20090329A1 (es)
RU (1) RU2009149370A (es)
TW (1) TW200914465A (es)
UY (1) UY31114A1 (es)
WO (1) WO2008150949A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US8515516B2 (en) 2004-07-13 2013-08-20 Dexcom, Inc. Transcutaneous analyte sensor
WO2006055778A2 (en) 2004-11-16 2006-05-26 Kalobios, Inc. Immunoglobulin variable region cassette exchange
CA2610340C (en) * 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
PT2361638E (pt) * 2005-12-12 2014-04-17 Ac Immune Sa Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas
PL2468770T3 (pl) * 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
BRPI0808227A2 (pt) 2007-03-14 2014-07-08 Taligen Therapeutics Inc Anticorpo humanizado anti-fator b
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN101998863B (zh) * 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
EP2238166B1 (en) 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2500361B1 (en) 2008-05-09 2016-03-30 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
AU2013202020B2 (en) * 2009-07-31 2014-11-27 F. Hoffmann-La Roche Ag Subcutaneous anti-HER2 antibody formulation
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
KR20130010114A (ko) 2010-03-03 2013-01-25 베링거 인겔하임 인터내셔날 게엠베하 바이파라토픽 ａ-베타 결합 폴리펩타이드
CN102958537B (zh) * 2010-04-07 2015-09-16 Abbvie公司 TNF-α结合蛋白
JP2013523182A (ja) * 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN102516360B (zh) * 2011-12-08 2013-11-06 清华大学 一种抑制β分泌酶酶切作用的多肽及其应用
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
EP3685854A1 (en) 2012-08-16 2020-07-29 Ipierian, Inc. Methods of treating a tauopathy
LT2906597T (lt) * 2012-10-15 2020-07-10 Medimmune Limited Antikūnai, atpažįstantys beta amiloidą
JP2017512751A (ja) * 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
MY202415A (en) 2015-11-03 2024-04-27 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
EP3999532A2 (en) * 2019-07-16 2022-05-25 Sanofi Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途
CN117491650B (zh) * 2023-11-01 2024-09-20 首都医科大学宣武医院 一种外周血Hb-Aβ复合物定量检测试剂盒、检测方法及应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529938A (en) * 1983-02-14 1985-07-16 Shell Oil Company High frequency induction method for locating the interface between formations having the same resistivity
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
JP2584613B2 (ja) * 1985-03-30 1997-02-26 バリベ、マール 組換えｄｎａ技術によってｄｎａ、ｒｎａ、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) * 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) * 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (da) * 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) * 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JP3672306B2 (ja) * 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
WO1992019244A2 (en) * 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
US5934272A (en) * 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5565352A (en) * 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
KR100479146B1 (ko) * 1995-04-21 2005-05-16 셀 제네시스, 인코포레이티드 큰게놈dna결실유발법
EP0850051A2 (en) * 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE508733T1 (de) * 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2252261T3 (es) * 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ES2405551T3 (es) * 2001-10-01 2013-05-31 Dyax Corporation Vectores de presentación eucariotas multicatenarios y usos de los mismos
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005035575A2 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CN101171031B (zh) * 2005-05-05 2011-09-28 默沙东公司 防止和治疗阿尔茨海默病的肽偶联物组合物和方法

Also Published As

Publication number Publication date
CA2687414A1 (en) 2008-12-11
CN101827862A (zh) 2010-09-08
RU2009149370A (ru) 2011-07-10
CO6251291A2 (es) 2011-02-21
UY31114A1 (es) 2009-01-05
KR20100032398A (ko) 2010-03-25
US20090175847A1 (en) 2009-07-09
EP2150563A1 (en) 2010-02-10
ECSP099833A (es) 2010-01-29
PA8782201A1 (es) 2009-02-09
TW200914465A (en) 2009-04-01
PE20090329A1 (es) 2009-03-27
AU2008260062A1 (en) 2008-12-11
IL202243A0 (en) 2010-06-16
JP2010530740A (ja) 2010-09-16
BRPI0812005A2 (pt) 2019-09-24
DOP2009000269A (es) 2009-12-15
WO2008150949A1 (en) 2008-12-11
CR11179A (es) 2010-05-27
AR066794A1 (es) 2009-09-09
MX2009012950A (es) 2010-03-26

Similar Documents

Publication Publication Date Title
CL2008001580A1 (es) Anticuerpo que se une al glibulomero beta amiloide abeta(20-42); acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; metodo para tratar una enfermedad relacionada con glomerulo abeta (20-42) y diagnosticar una enfermedad asociada a este globulomero abeta(20-42).
CL2008001741A1 (es) Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides.
CL2014001334A1 (es) Una proteina de union, anticuerpos o fragmentos del mismo que se une a her-3; molecula de acido nucleico que la codifica; procedimiento de produccion; composicion farmaceutica que lo comprende ; su uso para tratar enfermedades asociadas a her -3; y metodo de diagnostico de una enfermedad (div. sol. 3748-2006).
CL2013002888A1 (es) Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
CY1123619T1 (el) Καθαρισμος πρωτεϊνων
CR10298A (es) Metodos y composiciones para antagonismo de rage
CL2013000390A1 (es) Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer.
CO2018014325A2 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
BR112018000769A2 (pt) anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
BR112015006060A2 (pt) agentes de ligação kir3dl2
GT201200271A (es) Proteínas que se unen al tnf-a
CL2011002380A1 (es) Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende.
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
CL2008001742A1 (es) Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
CL2007002070A1 (es) Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
BRPI0821375B8 (pt) anticorpos biespecíficos, bivalentes, processo para a preparação destes e composição farmacêutica dos mesmos
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
BR112014021081A2 (pt) anticorpos para a metaloproteinase da matriz 9
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载